CN Patent

CN108601790B — C3肾小球病的治疗方法

Assigned to Chemocentryx Inc · Expires 2026-01-27 · 0y expired

What this patent protects

提供了治疗患有或易患C3肾小球病的人的方法，包括给予人有效量的C5aR拮抗剂。

USPTO Abstract

提供了治疗患有或易患C3肾小球病的人的方法，包括给予人有效量的C5aR拮抗剂。

Drugs covered by this patent

Tavneos (AVACOPAN) · Chemocentryx

Patent Metadata

Patent number: CN108601790B
Jurisdiction: CN
Classification: —
Expires: 2026-01-27
Drug substance claim: No
Drug product claim: No
Assignee: Chemocentryx Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.